Phase I trial of GBS‐01 for advanced pancreatic cancer refractory to gemcitabine
In this phase 1 clinical trial, 15 terminally ill cancer patients with mestatasticized pancreatic cancer were given an extract of Arctium lappa L. (burdock) arctigenin was orally administered, burdock extratcs have been reported to exert antitumor activity by attenuating the tolerance of cancer cells to glucose deprivation. Dose were up to 1.0g of burdock extract. None of the patients at any of the three dose levels showed any sign of toxicity. 33.3% showed positive signs from the treatment. 1 showed confirmed partial remition and 4 patients had a temporary halt in progression of the disease. This is in keeping with anecdotal reports of living longer with taking herbal supplements containing burdock extract.
Published:
Cancer Sci 107 (2016) 1818–1824
Attribution:
Masafumi Ikeda,corresponding author 1 Akihiro Sato, 2 Nobuo Mochizuki, 3 Kayo Toyosaki, 2 Chika Miyoshi, 4 Rumi Fujioka, 4 Shuichi Mitsunaga, 1 Izumi Ohno, 1 Yusuke Hashimoto, 1 Hideaki Takahashi, 1 Hiromi Hasegawa, 2 Shogo Nomura, 5 Ryuji Takahashi, 6 Satoshi Yomoda, 6 Katsuya Tsuchihara, 4 Satoshi Kishino, 3 and Hiroyasu Esumi 4 , 7